van de Putte, L B A <br/><br/>
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.  [electronic resource] 

 -  Annals of the rheumatic diseases  Dec 2003 
 - 1168-77 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0003-4967 
<br/><br/><label>Standard No.: </label>10.1136/ard.2003.009563  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis, Rheumatoid--drug therapy<br/>Double-Blind Method<br/>Drug Resistance<br/>Female<br/>Humans<br/>Injections, Subcutaneous<br/>Male<br/>Middle Aged<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors